Free Trial
NASDAQ:GNPX

Genprex 5/15/2024 Earnings Report

Genprex logo
$0.21 -0.01 (-5.90%)
Closing price 09/24/2025 04:00 PM Eastern
Extended Trading
$0.21 +0.00 (+0.39%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genprex EPS Results

Actual EPS
-$3.69
Consensus EPS
-$2.54
Beat/Miss
Missed by -$1.15
One Year Ago EPS
N/A

Genprex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genprex Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Genprex's next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Genprex Earnings Headlines

Genprex (NASDAQ:GNPX) Stock Price Down 5.7% - Should You Sell?
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Genprex Stockholders Approve Key Proposals at Annual Meeting
See More Genprex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email.

About Genprex

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes. This preclinical program seeks to deliver genes that support insulin production and glucose regulation, laying the groundwork for future clinical development in metabolic diseases. By leveraging its gene delivery platform, the company aims to expand its pipeline into other oncology and metabolic indications over time.

Headquartered in Austin, Texas, Genprex operates under a management team with deep experience in gene therapy research and biopharmaceutical development. The company collaborates with leading academic and clinical research centers to conduct its studies, ensuring rigorous trial design and patient enrollment. Through these partnerships, Genprex seeks to translate cutting-edge genetic science into transformative therapies for patients with high-unmet medical needs.

View Genprex Profile

More Earnings Resources from MarketBeat